Kinetic studies of novel inhibitors of endomorphin degrading enzymes

8Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Endomorphins (EMs), two endogenous l-opioid receptor selective ligands, are attractive lead compounds for opioid-based pain management studies. However, these peptides are quickly degraded by peptidases, in particular by dipeptidylpeptidase IV (DPP IV) and aminopeptidase M (APM). Targeting enzymatic degradation is one approach to prolong endomorphin activity. In this study we characterized the action of two new inhibitors of similar to endomorphins structure, Tyr-Pro-Ala-NH 2 (EMDB-2) and Tyr-Pro-Ala-OH (EMDB-3), which were designed earlier in our laboratory. The presented data give evidence that EMDB-2 and EMDB-3 are potent inhibitors of enzymes responsible for endomorphin cleavage. These compounds are stable and easily synthesized. EMDB-2 and EMDB-3 are competitive inhibitors of both, DPP IV and APM, with K i values in micromolar range. They are less potent than diprotin A in protecting EMs against DPP IV but more potent than actinonin in protecting these peptides against APM. © Springer Science+Business Media, LLC 2011.

Cite

CITATION STYLE

APA

Perlikowska, R., Fichna, J., Do-Rego, J. C., Gach, K., & Janecka, A. (2012). Kinetic studies of novel inhibitors of endomorphin degrading enzymes. Medicinal Chemistry Research, 21(7), 1445–1450. https://doi.org/10.1007/s00044-011-9666-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free